Home » Stocks » Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc. (FENC)

Stock Price: $8.45 USD 0.12 (1.44%)
Updated Jul 31, 2020 4:00 PM EDT - Market closed
Pre-market: $8.89 +0.44 (5.21%) Aug 3, 8:09 AM

Stock Price Chart

Key Info

Market Cap 214.26M
Revenue (ttm) n/a
Net Income (ttm) -13.98M
Shares Out 25.36M
EPS (ttm) -0.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 31, 2020
Last Price $8.45
Previous Close $8.33
Change ($) 0.12
Change (%) 1.44%
Day's Open -
Day's Range 8.28 - 8.68
Day's Volume 345,362
52-Week Range 3.91 - 9.75

More Stats

Market Cap 214.26M
Enterprise Value 204.36M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 25.36M
Float 19.54M
EPS (basic) -0.7
EPS (diluted) -0.70
FCF / Share -0.52
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.36M
Short Ratio 3.02
Short % of Float 7.09%
Beta 0.25
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 24.96
Revenue n/a
Operating Income -14.16M
Net Income -13.98M
Free Cash Flow -10.33M
Net Cash 9.90M
Net Cash / Share 0.39
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -57.07%
ROE -101.02%
ROIC 1,254.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(101.18% upside)
Current: $8.45
Target: 17.00
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-13.01-10.41-6.95-2.87-1.89-2.88-1.93-3.62-3.44-4.60
Net Income-12.78-9.89-7.05-2.79-0.66-2.181.85-5.164.69-7.82
Shares Outstanding19.9018.9415.0112.7710.839.879.728.397.995.34
Earnings Per Share-0.64-0.52-0.47-0.22-0.06-0.220.17-0.630.57-1.47
Operating Cash Flow-9.06-7.83-3.64-2.12-1.86-1.70-2.21-2.99-3.23-1.93
Free Cash Flow-9.06-7.83-3.64-2.12-1.86-1.70-2.21-2.99-3.23-1.93
Cash & Equivalents13.6522.7828.263.930.942.311.662.305.305.95
Total Debt--
Net Cash / Debt13.6522.7828.093.890.860.99-1.202.305.305.95
Book Value11.8821.3126.763.570.550.61-1.46-4.96-0.12-4.92
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Fennec Pharmaceuticals Inc.
Country United States
Employees 5
CEO Rostislav C. Raykov

Stock Information

Ticker Symbol FENC
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: FENC
IPO Date June 5, 2001


Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.